49,267
edits
Difference between revisions of "Foregut primary carcinomas"
Jump to navigation
Jump to search
Foregut primary carcinomas (view source)
Revision as of 14:51, 29 August 2025
, 14:51, 29 August 2025→IHC
(→IHC) |
(→IHC) |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 18: | Line 18: | ||
*CK20 -ve. | *CK20 -ve. | ||
*CDX2 -ve. | *CDX2 -ve. | ||
*[[HNF-1beta]] +ve (72-87% of cases +ve in one study<ref name=pmid30065837>{{cite journal |authors=Yang MX, Coates RF, Ambaye A, Gardner JA, Zubarick R, Gao Y, Skelly J, Liu JG, Mino-Kenudson M |title=Investigation of HNF-1B as a diagnostic biomarker for pancreatic ductal adenocarcinoma |journal=Biomark Res |volume=6 |issue= |pages=25 |date=2018 |pmid=30065837 |pmc=6062876 |doi=10.1186/s40364-018-0139-6 |url=}}</ref>). | |||
A (query) foregut primary panel for liver lesions: | A (query) foregut primary panel for liver lesions: | ||
*AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, TTF-1. | *AE1/AE3, CK7, CK20, CK19, CDX2, HepPar-1, CA-125, GATA3, PAX8, WT-1, TTF-1. | ||
*[[MMR]] (MLH1, MSH2, MSH6, PMS2). | |||
==Molecular== | |||
*FGFR2 mutation - seen in choleangiocarcinoma.<ref>{{cite journal |authors=Vogel A, Segatto O, Stenzinger A, Saborowski A |title=FGFR2 Inhibition in Cholangiocarcinoma |journal=Annu Rev Med |volume=74 |issue= |pages=293–306 |date=January 2023 |pmid=36170665 |doi=10.1146/annurev-med-042921-024707 |url=}}</ref> | |||
==See also== | ==See also== | ||